Menu Search
Equities

LILLY DRN ED

LILY34:SAO

LILLY DRN ED

Actions
  • Price (BRL)140.02
  • Today's Change2.26 / 1.64%
  • Shares traded917.00
  • 1 Year change+99.83%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 16:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LLY:NYQ since
announced		Transaction
value
Mablink Bioscience SASAnnounced17 Oct 202317 Oct 2023Announced31.91%--
POINT Biopharma Global IncDeal completed03 Oct 202303 Oct 2023Deal completed51.11%1.38bn
Versanis Bio IncAnnounced14 Jul 202314 Jul 2023Announced87.12%1.93bn
Emergence Therapeutics AGAnnounced29 Jun 202329 Jun 2023Announced77.33%8.33m
Sigilon Therapeutics IncDeal completed29 Jun 202329 Jun 2023Deal completed77.33%316.64m
Data delayed at least 15 minutes, as of May 23 2024 16:19 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Caixa DTVM SAas of 31 Jan 2024421.31k0.00%
Western Asset Management Company DTVM Ltda.as of 31 Jan 2024201.84k0.00%
Bram Bradesco Asset Management S/A DTVMas of 31 Jan 202449.01k0.00%
Safra Asset Management Ltda.as of 31 Jan 202444.90k0.00%
Warren Brasil Gest�o e Administra��o e Recursos Ltda.as of 31 Jan 202411.74k0.00%
BTG Pactual WM Gest�o de Recursos Ltda.as of 31 Jan 20242.45k0.00%
XP Allocation Asset Management Ltda.as of 31 Jan 2024970.000.00%
More ▼
Data from 31 Jan 2024 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.